| # | Drug | Count |
|---|---|---|
| 0 | TACROLIMUS | 33 |
| 1 | TACROLIMUS EXTENDED-RELEASE CAPSULES | 32 |
| 2 | TACROLIMUS OINTMENT 0.1% | 32 |
| 3 | MYCOPHENOLATE MOFETIL | 31 |
| 4 | MYCOPHENOLATE MOFETIL HYDROCHLORIDE | 31 |
| 5 | PREDNISONE | 28 |
| 6 | SIROLIMUS | 15 |
| 7 | PEMBROLIZUMAB | 14 |
| 8 | METOPROLOL | 9 |
| 9 | METOPROLOL TARTRATE | 9 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ALDESLEUKIN | 3 | 0.0024 |
| 1 | HALOBETASOL PROPIONATE | 3 | 0.0022 |
| 2 | PENTOXIFYLLINE | 5 | 0.0012 |
| 3 | SIROLIMUS | 15 | 0.0011 |
| 4 | CEMIPLIMAB-RWLC | 2 | 0.0010 |
| 5 | ACITRETIN | 3 | 0.0006 |
| 6 | MECHLORETHAMINE HYDROCHLORIDE | 1 | 0.0004 |
| 7 | GEMFIBROZIL | 4 | 0.0003 |
| 8 | AZILSARTAN KAMEDOXOMIL | 1 | 0.0003 |
| 9 | BARICITINIB | 1 | 0.0003 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Lymphocyte Growth Factor [EPC] | 3 | 0.0024 |
| 1 | Blood Viscosity Reducer [EPC] | 5 | 0.0012 |
| 2 | Adenosine Receptor Agonist [EPC] | 4 | 0.0005 |
| 3 | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] | 4 | 0.0002 |
| 4 | Epidermal Growth Factor Receptor Antagonist [EPC] | 8 | 0.0002 |
| 5 | SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC] | 2 | 0.0002 |
| 6 | Human Immunoglobulin G [EPC] | 3 | 0.0001 |
| 7 | Antimetabolite Immunosuppressant [EPC] | 3 | 0.0001 |
| 8 | Bile Acid [EPC] | 2 | 0.0001 |
| 9 | Peroxisome Proliferator Receptor alpha Agonist [EPC] | 4 | 0.0001 |